The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed ? the first clinical trial of a cancer vaccine using novel ROP technology.
Administrator2023-03-29view:1721
The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed ? the first clinical trial of a cancer vaccine using novel ROP technology.